Targeting of XIAP combined with systemic mesenchymal stem cell-mediated delivery of sTRAIL ligand inhibits metastatic growth of pancreatic carcinoma cells.
about
Harnessing the apoptotic programs in cancer stem-like cellsCancer nanotheranostics: improving imaging and therapy by targeted delivery across biological barriers.Immunotherapeutic organoids: a new approach to cancer treatmentMesenchymal stem cells as vectors for lung cancer therapyMesenchymal stem cells as delivery vectors for anti-tumor therapyIdentification of miRNA-7 by genome-wide analysis as a critical sensitizer for TRAIL-induced apoptosis in glioblastoma cells.TRAIL-receptor preferences in pancreatic cancer cells revisited: Both TRAIL-R1 and TRAIL-R2 have a licence to kill.The pro-metastatic role of bone marrow-derived cells: a focus on MSCs and regulatory T cellsTargeting X-linked inhibitor of apoptosis protein inhibits pancreatic cancer cell growth through p-Akt depletion.Mesenchymal stem cells engineered for cancer therapyMolecular targeted approaches for treatment of pancreatic cancer.DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer.TNF-α and IL-1β-activated human mesenchymal stromal cells increase airway epithelial wound healing in vitro via activation of the epidermal growth factor receptorDelivery of sTRAIL variants by MSCs in combination with cytotoxic drug treatment leads to p53-independent enhanced antitumor effectsPotential application of temozolomide in mesenchymal stem cell-based TRAIL gene therapy against malignant gliomaE1A-engineered human umbilical cord mesenchymal stem cells as carriers and amplifiers for adenovirus suppress hepatocarcinoma in mice.Mesenchymal stromal cells as vehicles of tetravalent bispecific Tandab (CD3/CD19) for the treatment of B cell lymphoma combined with IDO pathway inhibitor D-1-methyl-tryptophan.Understanding tumor-stroma interplays for targeted therapies by armed mesenchymal stromal progenitors: the Mesenkillers.Concise review: genetically engineered stem cell therapy targeting angiogenesis and tumor stroma in gastrointestinal malignancy.Pancreatic cancer gene therapy: from molecular targets to delivery systems.Immunomodulatory nature and site specific affinity of mesenchymal stem cells: a hope in cell therapy.Translation, but not transfection limits clinically relevant, exogenous mRNA based induction of alpha-4 integrin expression on human mesenchymal stem cells.Human umbilical cord mesenchymal stem cells delivering sTRAIL home to lung cancer mediated by MCP-1/CCR2 axis and exhibit antitumor effects.Harnessing mesenchymal stem cell homing as an anticancer therapy.Mesenchymal stromal cell delivery of full-length tumor necrosis factor-related apoptosis-inducing ligand is superior to soluble type for cancer therapy.The novel fusion protein sTRAIL-TMTP1 exhibits a targeted inhibition of primary tumors and metastases.TRAIL-engineered pancreas-derived mesenchymal stem cells: characterization and cytotoxic effects on pancreatic cancer cells.Mesenchymal stem cell-mediated cancer therapy: A dual-targeted strategy of personalized medicine.Bypassing the need for pre-sensitization of cancer cells for anticancer TRAIL therapy with secretion of novel cell penetrable form of Smac from hA-MSCs as cellular delivery vehicle.The role of apoptosis in the pathology of pancreatic cancerEngineered Mesenchymal Stem Cells as an Anti-Cancer Trojan Horse.Bone marrow-derived cells contribute to NDEA-induced lung squamous cell carcinoma.Human mesenchymal stem cell-derived iron oxide exosomes allow targeted ablation of tumor cells via magnetic hyperthermia.Caspase-10: a molecular switch from cell-autonomous apoptosis to communal cell death in response to chemotherapeutic drug treatment.Mesenchymal Stem Cell Expressing TRAIL as Targeted Therapy against Sensitised Tumour
P2860
Q26801037-A43E12F1-60EE-4038-856F-7D3CC1E7EDADQ26830028-A6EDDBFC-44DD-4B76-9FAC-D2B3A7778EAEQ26853431-C11CE1E2-3F43-4A8D-A819-E63EEEF844D4Q26853498-E0B5DB13-BAED-4DF7-BD8C-85D3077DE130Q26861201-2A0A1E34-ED83-4550-BF5A-894E29854534Q30854013-40D86105-D417-439C-8510-B52E31B937B9Q35681794-466BB333-89EC-416E-8ED4-5073CDE4D360Q35931795-D79230A9-44E7-49A3-937F-31A95F4A0757Q36049901-61AB3625-B0B4-48AC-A997-6BDFDD48B177Q36092724-39C2C3F5-BAE7-40FA-8D00-745D548110E5Q36174910-CBFB26B6-70D6-4730-9952-5B21858B01B0Q36215003-62E56753-3C78-4511-8A76-D595DBBDDBFAQ36454721-E483F2D6-05CE-4D68-A598-4E473EE87969Q37073589-4F777DFA-45AD-49B5-8193-4A0ED22ADF51Q37585453-96A46B47-32F2-452E-B778-5CD1A202F3EFQ37588372-BAB1D139-18DD-4555-98E1-6A5BC8061B3CQ37661559-5FFCE335-D5EB-4D08-B6A7-5FDC071C52EAQ37948053-04B550CD-7D42-44A1-AE25-9D3A0E1C82D8Q38058289-9EE9B42F-2109-4B31-8B20-C0025C8EBB8FQ38161331-105DC8CB-88C7-4B0A-A8E7-8DDEC34126BCQ38177278-F2F61BBD-6E1B-414B-BF4B-1C5C5A3C0902Q38691354-37D0855D-0E55-4EBF-AE26-D9C5B98F959AQ38806320-B61E715B-671C-42E6-9148-F9E8E0E93695Q38857484-0B37E0CD-3D6E-4657-9ECD-2D21C694C632Q38885494-8EE17835-2D82-433D-9CC2-E7CC1B4BB28BQ39070809-9B6CC961-FED4-4A0F-A9F8-9EB2DAB2D171Q39319003-DB9F24E3-AB2B-4D0A-AEFA-83372308C643Q39863924-E3B2AB27-4F9E-44DF-86E1-9AE90495600DQ41586384-21ED0D1C-E303-4C55-91CE-89052937964DQ42212254-5FDC0D73-D850-4CB7-B573-097F21E16755Q42391294-B2B0BBB8-CF23-43C4-BCEF-932B41354C81Q43562059-AF925868-0FB6-47A3-8897-9335925AC8F4Q45338034-4CD5F71C-6B2C-4E8D-A859-6767D3656D77Q47384260-4ABB401B-757B-4A54-A868-8EF9C07388D5Q57174410-E1B22367-3B51-4CB9-A2BE-2602328D156E
P2860
Targeting of XIAP combined with systemic mesenchymal stem cell-mediated delivery of sTRAIL ligand inhibits metastatic growth of pancreatic carcinoma cells.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Targeting of XIAP combined wit ...... of pancreatic carcinoma cells.
@en
Targeting of XIAP combined wit ...... of pancreatic carcinoma cells.
@nl
type
label
Targeting of XIAP combined wit ...... of pancreatic carcinoma cells.
@en
Targeting of XIAP combined wit ...... of pancreatic carcinoma cells.
@nl
prefLabel
Targeting of XIAP combined wit ...... of pancreatic carcinoma cells.
@en
Targeting of XIAP combined wit ...... of pancreatic carcinoma cells.
@nl
P2093
P50
P356
P1433
P1476
Targeting of XIAP combined wit ...... of pancreatic carcinoma cells.
@en
P2093
Laura Deedigan
Mairead Reidy
Stella Maris Albarenque
P304
P356
10.1002/STEM.533
P577
2010-11-01T00:00:00Z